Contract Management for Biotech (2026)

Contract management for biotech means keeping control of the agreements that govern a biotech company's two most valuable things: its intellectual property and the materials, data and partners it needs to develop that IP into a product. The defining risk is that biotech contracts allocate rights to things that may be worth nothing today and a great deal later, a research program, a molecule, a dataset, so a loose IP or publication clause signed early can quietly give away or encumber the asset the whole company is built on. Good contract management keeps those rights, obligations and deadlines visible from the lab bench through to the clinic. This page sets out the real contract types, the risks inside them and a practical workflow. It is general information, not legal advice. ## The contracts that run a biotech company Biotech contracting looks different from most industries because so much of it happens before there is a product to sell: - Material transfer agreements (MTAs). Govern the transfer of biological materials (cell lines, reagents, samples, compounds) between institutions, with limits on use, publication, onward transfer and rights in any results. The Uniform Biological Material Transfer Agreement (UBMTA) is a common academic baseline.

• Research collaboration and sponsored research agreements. Set up joint or funded research, and crucially allocate ownership and licence rights in what the research produces. These are where foundational IP is won or lost.
• Licensing agreements (in and out). License a patent, platform or compound in from a university or partner, or out to a larger developer, with upfront payments, milestones, royalties, field and territory limits, and diligence obligations.
• CRO and CMO agreements. Contract research organisations run studies and trials; contract manufacturing organisations make material. Both carry quality, data, IP and regulatory obligations.
• Clinical trial agreements (CTAs). Govern trials at sites and hospitals, covering subject injury, indemnity, data, publication and IP in trial results.
• Confidentiality and consulting agreements. With advisors, academics and key scientists, where IP assignment and confidentiality terms are central.
• Grant, funding and investment agreements. Public grants and investor terms that can carry IP, reporting and march-in style conditions.
• Quality and regulatory agreements. Define responsibilities for GxP compliance, often as a separate quality agreement alongside the commercial contract. Biotech sits close to pharma but the emphasis is earlier in the chain: research, materials and licensing rather than large-scale manufacturing and distribution. ## Where the risk actually lives ### IP ownership and licensing The single biggest risk. Who owns the invention made under a collaboration or sponsored research? What exactly was licensed in, and is the company free to sublicense it to a partner later? A gap between an in-licence and an out-licence, or an ambiguous collaboration IP clause, can block a deal years later. These terms deserve the closest reading in the whole portfolio. ### Publication and confidentiality Academic partners want to publish; a company needs to file patents first and protect trade secrets. MTAs, CTAs and collaboration agreements all carry publication-review windows and confidentiality terms that must be honoured to preserve patentability and the deal's value. ### Milestones, royalties and diligence Licences are full of dated and event-driven obligations: milestone payments on reaching a development stage, royalty reporting, and diligence obligations to actually develop the asset. Miss a diligence milestone and a licensor may have termination or reversion rights. These need tracking as live obligations, not filed terms. ### Data, materials and onward transfer MTAs restrict what you can do with materials and who you can pass them to. Breaching an onward-transfer limit, or using material outside the permitted field, can create liability and taint downstream results. ### Regulatory and quality responsibility CRO, CMO and CTA relationships split GxP and regulatory duties between parties. A quality agreement that does not match the commercial contract leaves gaps that surface during an inspection. ### Indemnity and subject injury Clinical trial agreements allocate liability for injury to trial subjects and carry insurance requirements. These are heavily negotiated and institution-specific. ## A practical contract management workflow 1. Build an IP-centred register. Organise contracts around the assets they touch: which agreements grant, encumber or depend on each program, molecule or platform, so the chain from in-licence to collaboration to out-licence is visible in one view.

2. Extract the obligations that bite. Milestone and royalty events, diligence deadlines, publication-review windows, reporting duties, material-use and onward-transfer limits, and licence expiry or renewal dates. Put each on a calendar with an owner.
3. Map the IP flow. For every program, know what was licensed in, what the company owns, what it can sublicense, and what a partner would need. Keep that map tied to the underlying contracts.
4. Align quality and commercial terms. Check that quality agreements match the CRO and CMO contracts and that regulatory responsibilities have no gaps.
5. Protect filing and publication. Track publication-review windows so patents are filed before disclosure, and confidentiality obligations are met.
6. Prepare for diligence. Investors and acquirers scrutinise the IP chain. A clean, linked contract register is also the fastest route through a financing or acquisition data room. ## How it differs by jurisdiction - India. A growing biotech and bio-manufacturing base, with contracts touching the Patents Act, biodiversity and access-and-benefit-sharing rules for biological resources, clinical trial regulation under the applicable drug rules, and data protection duties. Cross-border material and data transfers add export and compliance layers. Treat India-specific regulatory depth as the layer to get right first.

• US, UK, EU and others. US university licensing often runs under Bayh-Dole-derived terms with federal march-in and reporting conditions; the EU and UK add their own clinical trial and data regimes. The contract types are similar everywhere, but IP-ownership defaults, trial rules and data transfer requirements differ, so do not assume one template fits every country. Where governing law matters, set it explicitly. ## A quick checklist - Is every contract linked to the asset or program it affects?
• Is the IP chain (in-licence to collaboration to out-licence) mapped and consistent?
• Are milestone, royalty and diligence obligations on a calendar with owners?
• Are publication-review windows tracked so patents are filed first?
• Do quality agreements match the CRO and CMO contracts?
• Is the register clean enough to survive an investor or acquirer data room? ## Bringing the portfolio into one workspace The recurring theme in biotech contracting is that the company's value lives in a web of IP rights spread across MTAs, collaborations, in-licences and out-licences, and that a single ambiguous clause or missed diligence milestone can encumber an asset for years. The obligations that matter are dated, event-driven and scattered across many documents and many counterparties. This is the kind of work an AI contract workspace is built to hold in one place: every agreement linked to the program it touches, the IP grants and milestones extracted, the publication and diligence deadlines surfaced in plain English, and an activity timeline showing what changed and when. If you want to see that single workspace idea, Adira is one example. The point is simply that a biotech company's contracts and the rights they govern belong together, not scattered across drives where the next financing or deal has to reassemble them under pressure.